USO 23079
A Phase III Randomized Trial of Hyperthermic Intraperitoneal Chemotherapy (HIPEC) with Cisplatin versus no HIPEC at the Time of Interval Cytoreductive Surgery followed by Niraparib Maintenance in Patients with Newly Diagnosed Stage III and IV Ovarian, Primary Peritoneal, and Fallopian Tube Cancer (Hyperthermic Ovarian Treatment Trial) (GOG-3068/HOTT)
Disease Types: GYN Cancer Research
Eligibility Requirements:
Pathologic diagnosis of high grade serous or endometroid
epithelial OC/FP/PPC
• Stage III or IV documented on CT/MRI
• Recommended to undergo neoadjuvant chemotherapy
• Candidate for iCRS
• Stage IV must have complete response of extra-abdominal
disease or deemed resectable with iCRS
• No gross residual disease or disease larger than 1 cm
following iCRS prior to randomization
• Myriad myChoice® HRD results available
• Prior treatment for OC other than 3-4 cycles of Plt-based
neoadjuvant chemo excluded
Available at: